Obermatt
See Similar Stocks →

Immix Biopharma

NAQ:IMMX · US45258H1068
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings95
Price/Book23
Dividend Yield—
Revenue Growth—
Profit Growth84
Capital Growth55
TSR 52w90
Leverage83
Liquidity24
Refinancing55
Combined—
Analyst Opinions20
Pro Holdings35
Opinion Changes50
Market Pulse49

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2012
Employees31
Websiteimmixbio.com
ISINUS45258H1068
Last UpdateApr 2, 2026
Index & Theme
ImmunologyStem Cell TherapyHematologyOncologyBiotechnologyGamingScience and Engineering

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the application of chimeric antigen receptor cell therapy (‘CAR-T’) in light chain (AL) Amyloidosis and select immune-mediated diseases. The company's lead cell therapy ca…

Similar Stocks

The companies this stock is ranked against.

Compare Immix Biopharma with its peers
Cartesian Therapeutics
NMQ:RNAC
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Shattuck Labs
NSQ:STTK
50
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →